MCM
SRPT icon

Mainstay Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Mainstay Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$16K – 337
2018
Q3 		$16K Hold
100
– – 0.01% 306
2018
Q2 		$13K Sell
100
-100
-50% -$9.43K 0.01% 307
2018
Q1 		$14K Sell
200
-100
-33% -$6.67K 0.01% 227
2017
Q4 		$17K Buy
+300
New +$15.9K 0.01% 234

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Mainstay Capital Management's SRPT Position: Q4 2018 in Review

Mainstay Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 100 shares — an estimated $16K sold.

Mainstay Capital Management first reported a position in SRPT in Q4 2017 and held it in 4 quarters. The position peaked at $17K in Q4 2017. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

  • Mainstay Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 100 Sarepta Therapeutics shares in Q4 2018, an estimated $16K.
  • Mainstay Capital Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 4 quarters.
  • Mainstay Capital Management's Sarepta Therapeutics position peaked at $17K in Q4 2017.
  • 335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.